Application of the QbD-based approach in the early development of liposomes for nasal administration.
暂无分享,去创建一个
Edina Pallagi | Piroska Szabó-Révész | Ildikó Csóka | Zsófia Németh | Orsolya Jójárt-Laczkovich | Orsolya Jójárt-Laczkovich | E. Pallagi | P. Szabó-Révész | I. Csóka | Z. Németh
[1] Selcan Türker,et al. Nasal route and drug delivery systems , 2004, Pharmacy World and Science.
[2] D. Deamer. From “Banghasomes” to liposomes: A memoir of Alec Bangham, 1921–2010 , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] A. Falcão,et al. Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice. , 2015, International journal of pharmaceutics.
[4] G. Amidon,et al. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[5] Edina Pallagi,et al. Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes. , 2018, Drug discovery today.
[6] Edina Pallagi,et al. New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach. , 2016, International journal of pharmaceutics.
[7] Hussain,et al. Intranasal drug delivery. , 1998, Advanced drug delivery reviews.
[8] R. Ambrus,et al. Preliminary study of nanonized lamotrigine containing products for nasal powder formulation , 2017, Drug design, development and therapy.
[9] J. Veuthey,et al. Strategies for formulating and delivering poorly water-soluble drugs , 2015 .
[10] T. Allen,et al. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. , 1993, Biochimica et biophysica acta.
[11] R. Ambrus,et al. Investigation of Absorption Routes of Meloxicam and Its Salt Form from Intranasal Delivery Systems , 2018, Molecules.
[12] V. Torchilin. Targeted pharmaceutical nanocarriers for cancer therapy and imaging , 2007, The AAPS Journal.
[13] L. Illum. Nasal drug delivery--possibilities, problems and solutions. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[14] Seemalata Jain,et al. Liposomal formulation of curcumin attenuates seizures in different experimental models of epilepsy in mice , 2013, Fundamental & clinical pharmacology.
[15] Hatem Fessi,et al. Preparation, Characterization and Applications of Liposomes: State of the Art , 2012 .
[16] Wei Zhang,et al. Effect of Freezing Rate on the Stability of Liposomes During Freeze-Drying and Rehydration , 1997, Pharmaceutical Research.
[17] Adriana O. Santos,et al. Nanosystems in nose‐to‐brain drug delivery: A review of non‐clinical brain targeting studies , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[18] M. Winterhalter,et al. Liposome stability and formation: experimental parameters and theories on the size distribution. , 1993, Chemistry and physics of lipids.
[19] Michael B. Bolger,et al. Application of Gastrointestinal Simulation for Extensions for Biowaivers of Highly Permeable Compounds , 2008, The AAPS Journal.
[20] J Helen Cross,et al. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance , 2012, BMJ : British Medical Journal.
[21] Edina Pallagi,et al. Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation. , 2015, International journal of pharmaceutics.
[22] R. Ambrus,et al. Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles. , 2015, International journal of pharmaceutics.
[23] D. Lamprou,et al. Influence of cholesterol on liposome stability and on in vitro drug release , 2015, Drug Delivery and Translational Research.
[24] Amit S. Patil,et al. Quality by Design (QbD) : A new concept for development of quality pharmaceuticals , 2013 .
[25] O. Dulac,et al. Lamotrigine in Treatment of 120 Children with Epilepsy , 1994, Epilepsia.
[26] G. Colombo,et al. Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting , 2018, Pharmaceutics.
[27] S. Garg,et al. Permeability issues in nasal drug delivery. , 2002, Drug discovery today.
[28] Lawrence X. Yu. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.
[29] A. Molinari,et al. Liposomes as nanomedical devices , 2015, International journal of nanomedicine.
[30] M. Parvathi. INTRANASAL DRUG DELIVERY TO BRAIN: AN OVERVIEW , 2012 .
[31] M. R. Mozafari,et al. Liposomes: A Review of Manufacturing Techniques and Targeting Strategies , 2011 .
[32] R. Ambrus,et al. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach , 2016, Drug design, development and therapy.
[33] Z. Zawada. A single-step method of liposome preparation. , 2004, Cellular & molecular biology letters.
[34] Soodabeh Davaran,et al. Liposome: classification, preparation, and applications , 2013, Nanoscale Research Letters.
[35] G. K. Raju,et al. Understanding Pharmaceutical Quality by Design , 2014, The AAPS Journal.